← Patent-cliff monitor small molecule AGAMREE VAMOROLONE
Loss of exclusivity July 2040 latest FDA-listed patent expiry
Company Catalyst
Drug detail Brand name AGAMREE Active ingredient VAMOROLONE Strength 40MG/ML Dosage form SUSPENSION Route ORAL Modality Small molecule FDA approval October 2023 Marketing status RX
Listed patents Patent Expires Type 11382922 July 2040 substance, product 11471471 March 2040 use U-3747 12201639 March 2040 substance, product 11690853 March 2033 use U-3747 10857161 May 2029 product 8334279 May 2029 use U-3747 11833159 May 2029 product
Regulatory exclusivity Code Expires ODE-450 October 2030 NCE October 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.